Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping.
In a pilot study two patients with brittle asthma and two with morning dipping received terbutaline or a placebo administered subcutaneously either by continuous infusion or in injections every six hours. In two patients brittle asthma was completely suppressed by terbutaline 1 mg/day given by either method. In the two others early morning dipping responded only to continuous subcutaneous infusions of terbutaline 12 mg/day. Terbutaline administered subcutaneously may be an effective treatment in asthmatic patients who show important diurnal variations in air flow.
D000328:Adult; D001249:Asthma / Q000503:physiopathology / Q000517:prevention & control*; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D010366:Peak Expiratory Flow Rate; D010865:Pilot Projects; D013726:Terbutaline / Q000008:administration & dosage* / Q000627:therapeutic use
D013726:Terbutaline